Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacabrutideg in Combination With Other Agents in Relapsed or Refractory B-Cell Malignancies
NCT06634589Phase 2Recruiting
- Sponsor
- BeOne Medicines
- Start
- Nov 2024
- Primary completion
- Dec 2028
- Countries
- 8
01
Overview
Phase 2, open-label trial of tacabrutideg in B-cell malignancy (8 arms), sponsored by BeOne Medicines. Primary endpoints: Dose-Limiting Toxicities up to 2 years and Adverse Events up to 2 years. Started Nov 2024; status: recruiting.
02
Drugs
tacabrutideg
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT06634589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634589.